InflaRx NV
IFRX
View Detailed Chart
1.110USD
+0.050+4.72%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
75.20MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.72%
5 Days
+5.71%
1 Month
-5.93%
6 Months
+39.59%
Year to Date
-55.06%
1 Year
-50.45%
View Detailed Chart
TradingKey Stock Score of InflaRx NV
Currency: USD Updated: 2025-12-19Key Insights
InflaRx NV's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 179/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.57.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
InflaRx NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
11.571
Target Price
+991.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
InflaRx NV Highlights
StrengthsRisks
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Growing
The company is in a growing phase, with the latest annual income totaling USD 152.79K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 152.79K.
Fairly Valued
The company’s latest PE is -2.12, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.63M shares, decreasing 25.13% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.71.
InflaRx NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
InflaRx NV Info
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Ticker SymbolIFRX
CompanyInflaRx NV
CEORiedemann (Niels C)
Websitehttps://www.inflarx.de/
FAQs
What is the current price of InflaRx NV (IFRX)?
The current price of InflaRx NV (IFRX) is 1.110.
What is the symbol of InflaRx NV?
The ticker symbol of InflaRx NV is IFRX.
What is the 52-week high of InflaRx NV?
The 52-week high of InflaRx NV is 2.770.
What is the 52-week low of InflaRx NV?
The 52-week low of InflaRx NV is 0.711.
What is the market capitalization of InflaRx NV?
The market capitalization of InflaRx NV is 75.20M.
What is the net income of InflaRx NV?
The net income of InflaRx NV is -46.06M.
Is InflaRx NV (IFRX) currently rated as Buy, Hold, or Sell?
According to analysts, InflaRx NV (IFRX) has an overall rating of Buy, with a price target of 11.571.
What is the Earnings Per Share (EPS TTM) of InflaRx NV (IFRX)?
The Earnings Per Share (EPS TTM) of InflaRx NV (IFRX) is -0.523.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%Popular Symbols
